What is Elrexfio and what is it used for?

Elrexfio is a cancer medicine that contains the active substance elranatamab. It is used to treat adults with a type of cancer of the bone marrow called multiple myeloma.

It is used by itself for patients whose cancer has returned (relapsed) and stopped responding to previous treatments (refractory), who have had at least three other kinds of treatment and whose cancer has worsened since receiving the last treatment.

Elrexfio is an antibody, a type of protein, which has been designed to recognise and attach to specific targets in your body. Elrexfio targets B-cell maturation antigen (BCMA), which is found on multiple myeloma cancer cells, and cluster of differentiation 3 (CD3), which is found on T lymphocytes, a particular kind of white blood cell in your immune system. This medicine works by attaching to these targets and, by doing so, bringing the cancer cells and T cells together. This helps your immune system destroy the multiple myeloma cancer cells.

Elrexfio can only be obtained with a prescription.

Reference Information

If you would like to see the Summary of Product Characteristics (SPC) or Patient Information Leaflet (PIL) for Elrexfio visit the electronic Medicines Compendium (eMC).

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

If you get any side effects when taking this or any other medicine, talk to your doctor or other relevant health professional e.g. pharmacist, nurse. This includes any possible side effects not listed in the packaging leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk or search the Google Play or Apple App Store for MHRA Yellow Card. By reporting side effects, you can help provide more information on the safety of this medicine.

Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professional for specific, health-related advice and support.